Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

Supernus drug meets main goal of study in adults with ADHD

(Reuters) - Supernus Pharmaceuticals Inc said on Tuesday its experimental drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage study in adults.

The drug, SPN-812, was better able to improve symptoms of ADHD compared with a placebo, the company said.

SPN-812 is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in children 6 to 17 years of age.

Last month, the FDA declined to approve the drug for use in children, citing an issue related to the company’s laboratory that conducts analytical testing, which recently moved to a new location.

Supernus on Tuesday said it would meet the FDA in January to discuss the application.

If approved in children, the company said it would file an application with the agency for marketing SPN-812 to adults in the second half of next year.

The adult ADHD patient population represents about half of the total ADHD market in the United States, the company said.

DECEMBER 23, 2020

https://www.reuters.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies